

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original): A crystalline Form I of (S)-citalopram oxalate, characterized by an x-ray powder diffraction pattern having peaks expressed as  $2\theta$  at about 6.9, 8.9, 10.8, 13.4, 14.0, 16.3, 17.6, 18.6, 19.1, 19.5, 21.2, 22.8, 23.1, 24.2, 24.5, 25.3, 27.3 degrees.
2. (Original): A crystalline Form I of (S)-citalopram oxalate as defined in claim 1, further characterized by an x-ray powder diffraction pattern as in FIG. 1.
3. (Previously Presented): A process for preparation of Form I of (S)-citalopram oxalate as defined in claim 1, which comprises: a) mixing (S)-citalopram oxalate and a suitable solvent; and b) isolating Form I of (S)-citalopram oxalate; wherein the suitable solvent is selected from the group consisting of ethyl acetate, methyl tert-butyl ether and acetonitrile.
4. (Previously Presented): A process according to claim 3, wherein the suitable solvent is methyl tert-butyl ether.
5. (Original): A process according to claim 3, wherein the suitable solvent is ethyl acetate.

6. (Previously Presented): A process for preparation of Form I of (S)-citalopram oxalate as defined in claim 1, which comprises: a) adding oxalic acid to a solution of (S)-citalopram in a suitable solvent; b) isolating Form I of (S)-citalopram oxalate; wherein the suitable solvent is selected from the group consisting of ethyl acetate, methyl tert-butyl ether and acetonitrile.

7. (Previously Presented): A process according to claim 6, wherein the suitable solvent is methyl tert-butyl ether.

8. (Original): A crystalline Form II of (S)-citalopram oxalate, characterized by an x-ray powder diffraction pattern having peaks expressed as  $2\theta$  at about 6.6, 10.0, 11.0, 11.9, 15.2, 16.8, 17.8, 20.3, 21.1, 21.4, 22.6, 23.0, 26.4, 28.4 degrees.

9. (Original): A crystalline Form II of (S)-citalopram oxalate as defined in claim 8, characterized by an x-ray powder diffraction pattern as in FIG. 2.

10. (Previously Presented): A process for preparation of Form II of (S)-citalopram oxalate as defined in claim 8, which comprises: a) mixing (S)-citalopram oxalate and an alcoholic solvent; b) isolating Form II of (S)-citalopram oxalate; wherein the alcoholic solvent is selected from the group consisting of methanol and isopropyl alcohol.

11. (Original): A process according to claim 10, wherein the alcoholic solvent is

methanol.

12. (Original): A process according to claim 11, wherein Form II of (S)-citalopram oxalate is isolated by using diisopropyl ether as an anti-solvent.

13. (Previously Presented): A process for preparation of Form II of (S)-citalopram oxalate as defined in claim 8, which comprises: a) adding oxalic acid to a solution of (S)-citalopram in an alcoholic solvent; b) isolating Form II of (S)-citalopram oxalate; wherein the alcoholic solvent is selected from the group consisting of methanol and isopropyl alcohol.

14. (Original): A process according to claim 13, wherein the alcoholic solvent is methanol.

15. (Canceled)

16. (Canceled)